The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
-
UCLA Medical Center, Los Angeles, California, United States, 90095
James M Stockman Cancer Institute, Frederick, Maryland, United States, 21702
New York Cancer & Blood Specialists, Shirley, New York, United States, 11967
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599
Gabrail Cancer Center, Canton, Ohio, United States, 44718
JPS Health Network, Fort Worth, Texas, United States, 76104
Baylor Scott & White Research Institute, Temple, Texas, United States, 76508
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Elephas,
Fred Hausheer, MD, FACP, STUDY_DIRECTOR, Elephas
2026-12